NovoCure Limited · NASDAQ:NVCR
NovoCure — Fact Sheet (September 2023)
5 slides from NovoCure's fact sheet, September 2023
Slide 1: building a global oncology company
building a global oncology company Founded in 2000, Novocure develops and commercializes an innovative therapy for solid tumors: Tumor Treating Fields (TTFields). After more than 20 years, Novocure continues to grow, fueled by a collective drive for innovation.
Slide 2: our growth, at a glance
our growth, at a glance Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, TTFields. TTFields are + + 27,000 PATIENTS TREATED TO DATE 1,300 EMPLOYEES WORLDWIDE electr
Slide 3: our pipeline
TTFIELDS THERAPY IS A PLATFORM THERAPY, WITH SIGNIFICANT POTENTIAL FOR our pipeline VERSATILITY ACROSS SOLID TUMOR TYPES With several late-stage trials nearing completion, we are approaching AND LINES OF THERAPY. a critical inflection point for cancer patients and our company. Trial TTFields therapy
Slide 4: our global footprint
our global footprint Headquartered in Root, Switzerland and with “We are committed to making our therapy available to a growing global footprint, Novocure has all the patients who may benefit. We have a unique regional operating centers in Portsmouth, New opportunity to make an even larger impact as
Slide 5: For more information, visit novocure.com
For more information, visit novocure.com Follow @Novocure on Twitter and LinkedIn. Patient images reflect the health status of the patient(s) at the time each photo was taken. ©2023 Novocure GmbH. All Rights Reserved. Novocure is a registered trademark of Novocure GmbH. GLB-COMM-00488 March 2023 v2.